{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:29:59Z","timestamp":1794706199616,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZonMw","id":[{"id":"https:\/\/ror.org\/01yaj9a77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Stichting de Merel"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Risperidone is an atypical antipsychotic drug used to treat irritability and aggression in children and adolescents with autism spectrum disorder. In an earlier study, the sum trough concentration of risperidone and its metabolite (9-hydroxyrisperidone) was positively correlated with weight gain and effectiveness. The aim of this study was to determine the therapeutic window for risperidone sum trough concentrations that balances weight gain with treatment effectiveness in this population. In addition, the effect of therapeutic drug monitoring (TDM) on treatment optimization was simulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In a retrospective cohort (n = 24 children), the target window for risperidone leading to the least increase in body mass index z-scores while retaining effectiveness as measured by the irritability subscale of the Aberrant Behavior Checklist was determined using receiver operating curve analysis. This target range was used to simulate the effect of TDM using a population PK model implemented in the software platform InsightRX. Dosing advice was based on plasma trough concentrations and the dose administered at 12 weeks to simulate whether more children would be on target at 24 weeks after the start of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A risperidone sum trough target range of 3.5\u20137.0 mcg\/L would minimize increase in body mass index z-score and optimize effectiveness. Dosing advice using TDM and a population PK model would lead to a larger proportion of children achieving the target concentration range (62.5% versus 16.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TDM may be a useful tool for optimizing risperidone treatment in children and adolescents with autism spectrum disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001161","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T08:04:12Z","timestamp":1701245052000},"page":"259-264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-2246","authenticated-orcid":false,"given":"Rebecca A.","family":"Hermans","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus University Medical Center, Rotterdam, the Netherlands;"},{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands; and"},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaya E.M.","family":"Storm","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne M.","family":"Kloosterboer","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus University Medical Center, Rotterdam, the Netherlands;"},{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon H.J.","family":"Hillegers","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus University Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands; and"},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Dierckx","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry\/Psychology, Erasmus University Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands; and"},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s10803-013-2022-5","article-title":"Emotion dysregulation and the core features of autism spectrum disorder","volume":"44","author":"Samson","year":"2014","journal-title":"J Autism Dev Disord"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaac.2016.03.012","article-title":"Antipsychotic use trends in youth with autism spectrum disorder and\/or intellectual disability: a meta-analysis","volume":"55","author":"Park","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/cap.2018.0115","article-title":"Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis","volume":"29","author":"Fallah","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"623681","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The burden of antipsychotic-induced weight gain and metabolic syndrome in children","volume":"12","author":"Libowitz","year":"2021","journal-title":"Front Psychiatry"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinbiochem.2017.02.003","article-title":"Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders","volume":"50","author":"Srisawasdi","year":"2017","journal-title":"Clin Biochem"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/cap.2009.0071","article-title":"Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene","volume":"20","author":"Hoekstra","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bcp.14465","article-title":"Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder","volume":"87","author":"Kloosterboer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/FTD.0000000000000776","article-title":"Feasibility of dried blood spots in children with behavioral problems","volume":"42","author":"Kloosterboer","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/adc.2009.177592","article-title":"Facilitating pharmacokinetic studies in children: a new use of dried blood spots","volume":"95","author":"Patel","year":"2010","journal-title":"Arch Dis Child"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/FTD.0000000000000712","article-title":"Dried blood spot analysis for therapeutic drug monitoring of antipsychotics: drawbacks of its clinical application: erratum","volume":"41","author":"Kloosterboer","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R20-20250603","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.2191","article-title":"Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients","volume":"38","author":"Turner","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-0029-1239540","article-title":"Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy","volume":"43","author":"Klampfl","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","article-title":"Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone","volume":"129","author":"Taurines","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00787-020-01614-4","article-title":"Risk factors and pattern of weight gain in youths using antipsychotic drugs","volume":"30","author":"van der Esch","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12888-022-04445-6","article-title":"The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial","volume":"22","author":"Hermans","year":"2022","journal-title":"BMC Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:11:25Z","timestamp":1748956285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001161","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2023-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}